Showing results (41-50 of 108) with videos related to
Sort By:
Pageof 11
Frontiers in Oncology|March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.The Oncologist|May 8, 2026
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trialFélix Guerrero-Ramos, Carmen Gómez-Cañizo, Marta Rodríguez-Izquierdo, et al.Future Oncology (London, England)|April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancerSantiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.Cancer Treatment Reviews|May 10, 2024
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsLayal Rached, Ariane Laparra, Madona Sakkal, et al.JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.Cancer|February 23, 2022
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancerLuis Paz-Ares, David R Spigel, Yuanbin Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker AnalysesTony S K Mok, Sang-We Kim, Yi-Long Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.Pageof 11